Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

Summary

The study design includes a 3-dose randomization phase to determine effective doses of INCB047986 in patients with myelodysplastic syndrome (MDS) who are refractory or unlikely to respond to erythropoiesis-stimulating agents (ESAs) followed by an extension phase.

Timeline

Start

2014-01

Primary completion

2014-09

Completion

2014-09

Outcome

Outcome not reported

Stopped (Business): “Business decision.”

Drugs

Indications